← Browse by Condition
Medical Condition

progressive metastatic castrate resistant prostate cancer

Total Trials
1
Recruiting Now
1
Trial Phases
Phase 1, Phase 2
NCT07206056 Phase 1, Phase 2
Recruiting

An Open-label Dose Escalation and Expansion, Followed by a Phase II Study of Tulmimetostat (DZR123) and JSB462 (Luxdegalutamide) in Patients With Progressive Metastatic Castrate Resistant Prostate Cancer (mCRPC) (TulmiSTAR-01)

Enrollment
188 pts
Location
United States, Austr...
Sponsor
Novartis Pharmaceuticals
View Trial →